人胰腺癌細胞QGP-1

細胞名稱

人胰腺癌細胞QGP-1

貨物編碼

BFN60808595

產品規格

T25培養瓶x1

1.5ml凍存管x2

細胞數量

1x10^6

1x10^6

保存溫度

37℃

-198℃

運輸方式

常溫保溫運輸

干冰運輸

安全等級

1

用途限制

僅供科研      2類

培養體系

DMEM高糖培養基+10%FBS+1%三抗

培養溫度

37℃

二氧化碳濃度

5%

簡介

人胰腺癌細胞QGP-1取自61歲男性，該細胞源于JCRB

注釋

Part of: Cancer Cell Line Encyclopedia (CCLE) project.

Part of: COSMIC cell lines project.

Part of: NCI RAS program mutant KRAS cell line panel.

Doubling time: ~3.5 days (PubMed=7227711); 61 hours (PubMed=25984343); 1.6 +- 0.3 days (PubMed=29330294); ~42 hours (lot 04112012), ~2 days (lot 02162009), 40-50 hours (lot 04152003), ~74 hours (lot 05312016) (JCRB).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Deep exome analysis.

Omics: Deep quantitative proteome analysis.

Omics: Deep RNAseq analysis.

Omics: DNA methylation analysis.

Omics: shRNA library screening.

Omics: SNP array analysis.

Omics: Transcriptome analysis.

Misspelling: QGP; In CGH-DB 9375-4 and GEO GSM600373.

Misspelling: QCP-1; In DOI=10.5772/30884.

基因突變

Heterozygous for KRAS p.Gly12Val (c.35G>T) (PubMed=21607521; CCLE; Cosmic-CLP).

Heterozygous for TP53 p.Pro98fs*25 (c.293delC) (CCLE; Cosmic-CLP).

HLA信息

STR信息

Amelogenin        X

CSF1PO        10,12

D3S1358        14,17

D5S818        12

D7S820        12

D8S1179        14

D13S317        13

D16S539        10,12 (Cosmic-CLP; JCRB)

12 (PubMed=25877200)

D18S51        13

D21S11        29

FGA        21,23

Penta D        13

Penta E        5,24

TH01        6,9

TPOX        8,11

vWA        14,17,18 (JCRB)

14,18 (Cosmic-CLP; PubMed=25877200)

參考文獻

 PubMed=29330294; DOI=10.1158/1541-7786.MCR-17-0163

Benten D., Behrang Y., Unrau L., Weissmann V., Wolters-Eisfeld G., Burdak-Rothkamm S., Stahl F.R., Anlauf M., Grabowski P., Mobs M., Dieckhoff J., Sipos B., Fahl M., Eggers C., Perez D., Bockhorn M., Izbicki J.R., Lohse A.W., Schrader J.

Establishment of the first well-differentiated human pancreatic neuroendocrine tumor model.

Mol. Cancer Res. 16:496-507(2018)

PubMed=29444439; DOI=10.1016/j.celrep.2018.01.051

Yuan T.L., Amzallag A., Bagni R., Yi M., Afghani S., Burgan W., Fer N., Strathern L.A., Powell K., Smith B., Waters A.M., Drubin D., Thomson T., Liao R., Greninger P., Stein G.T., Murchie E., Cortez E., Egan R.K., Procter L., Bess M., Cheng K.T., Lee C.-S., Lee L.C., Fellmann C., Stephens R., Luo J., Lowe S.W., Benes C.H., McCormick F.

Differential effector engagement by oncogenic KRAS.

Cell Rep. 22:1889-1902(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023

Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E., Schweppe D.K., Jedrychowski M., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.

Quantitative proteomics of the Cancer Cell Line Encyclopedia.

Cell 180:387-402(2020)